Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Prospective Study on [68Ga]-Psma Pet/Ct Imaging in Newly Diagnosed Intermediate-And High-Risk Prostate Cancer Publisher



Harsini S1, 2 ; Fallahi B1 ; Ziarati NK1 ; Razi A3 ; Amini E4 ; Emamiardekani A1 ; Fardesfahani A1 ; Parizi MK5 ; Farzanehfar S6 ; Beiki D1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Nuclear Medicine, Tehran University of Medical sciences, Tehran, Iran
  2. 2. Association of Nuclear Medicine and Molecular Imaging (ANMMI), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Department of Urology, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Asia Oceania Journal of Nuclear Medicine and Biology Published:2021


Abstract

Objective(s): Prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) is an emerging modality to detect metastatic disease in patients with prostate cancer (PCa). This prospective study aimed to evaluate the role of [68Ga]-PSMA PET/CT in the initial workup of intermediate and high-risk PCa . Methods: Twenty-five patients with newly transrectal ultrasound biopsy-proven, untreated intermediate-and high-risk PCa (mean age, 68.5±6.2 years; range 55–83 years) were enrolled in this prospective study between September 2018 and June 2020 and underwent a [68Ga]-PSMA PET/CT examination. All images were analyzed both visually and semiquantitatively by measuring the maximum standardized uptake value (SUVmax) of the primary prostatic tumor and metastatic lesions. The diagnostic sensitivity of [68Ga]-PSMA PET/CT for the diagnosis of PCa was established by histopathology as the reference standard. The associations between SUVmax of the primary tumors and prostate-specific antigen (PSA) levels, Gleason scores (GSs), and metastatic extent of the disease were studied. Results: All patients had a positive [68Ga]-PSMA PET/CT exam. Seventeen patients (58%) showed [68Ga]-PSMA avidity in both prostate lobes and 8 (32%) had unilateral uptake. SUVmax in the primary tumor significantly correlated with serum PSA values (r=0.57, P=0.003). PSMA PET/CT depicted regional lymph node metastases in 32% of patients, distant lymph node metastases in 20%, osseous metastases in 16% and pulmonary metastases in 8% of patients. Sixty percent of PSMA-positive bone metastases and 21.4% of intraprostatic tumoral lesions were missed on the contemporaneous bone scintigraphy and magnetic resonance imaging, respectively. Conclusion: [68Ga]-PSMA PET/CT shows promise as a valuable imaging modality with high diagnostic sensitivity in the setting of intermediate and high-risk PCa. Moreover, the SUVmax of the primary tumor has a positive correlation with PSA levels at the time of the scan. © 2021 mums.ac.ir All rights reserved.